TRxADE Health reduces officer cash salaries, issues stock; director Jennings resigns

Scienture Holdings, Inc.

Christine Jennings resigned as director effective Aug 26, 2022; no disagreement stated.
CEO Ajjarapu's base salary reduced from $360k to $300k cash plus $60k in stock for 12 months.
President Patel and CFO Huffman took cash salary cuts of $10k and $25k respectively, replaced with stock.
Employees accepted $37k aggregate cash reduction for 31,896 restricted shares.
Independent director annual cash retainer cut to $26,750; each director gets 54,525 shares valued at $63,250.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Christine L. Jennings

Director

SCNX · Scienture Holdings, Inc.

Effective: 2022-08-26
Filed: September 1, 2022, 7:59 PM ET

On August 26, 2022, Christine L. Jennings resigned as a member of the Board of Directors of TRxADE HEALTH, INC.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Christine L. Jennings resigned as Director at Scienture Holdings, Inc..

Action: resigned
Role: Director

Exact text from the filing

On August 26, 2022, Christine L. Jennings resigned as a member of the Board of Directors of TRxADE HEALTH, INC.

View on SEC.gov

Scienture Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-024846

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.